EMA Reports Near-Record 104 Medicine Approvals in 2025 with Strategic Focus on Cardiovascular Health

The European Medicines Agency (EMA) convened a comprehensive press briefing to dissect the regulatory milestones of 2025, a year characterized by a significant surge in therapeutic innovation and a robust pipeline for the future. Led by Chief Medical Officer Dr. Steffen Thirstrup and Francesca Day, Head of Therapeutic Areas at EMA, the briefing underscored a pivotal era for European public health, marked by the second-highest number of medicine recommendations in fifteen years. The agency’s year-end review highlighted a strategic pivot toward addressing chronic silent killers, specifically through the lens of the European Commission’s Safe Hearts plan, while navigating the complexities of emerging artificial intelligence and legislative shifts.

Surge in New Active Substances and Biosimilar Dominance

The regulatory landscape in 2025 saw the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommend 104 medicines for approval, a figure only surpassed once in the last decade and a half. Within this total, 38 products—representing approximately 36.5%—contained new active substances that had never previously been authorized within the European Union. This influx of novelty was particularly evident in the orphan drug sector, where 16 new active substances were recommended to treat rare conditions affecting fewer than 5 in 10,000 EU citizens.

While oncology remained a powerhouse of innovation with 14 of its 18 approvals featuring new active substances, endocrinology emerged as the numerically strongest category with 29 total recommendations. A significant driver of this volume was the unprecedented expansion of the biosimilar market. The agency reported 41 biosimilar approvals, the highest annual count to date, of which 23 specifically used denosumab for the treatment of osteoporosis and bone loss. This milestone reflects twenty years of EMA experience in the biosimilar space, during which the agency has assessed 180 products and approved 160 without identifying significant safety or efficacy concerns.

Addressing Unmet Needs in Cardiovascular and Metabolic Care

A primary focus of the briefing was the escalating public health burden of cardiovascular disease, which remains the leading cause of death in Europe, claiming 1.7 million lives annually. The agency noted that risk factors are trending upward, with 54% of adults now classified as overweight and 25% suffering from hypertension. In response, the EMA is aligning its regulatory efforts with the EU Safe Hearts plan, prioritizing treatments that manage not only heart disease but also interconnected conditions like obesity and diabetes.

Notable approvals in this sector included Teplizumab, the first treatment authorized to delay the onset of stage 3 type 1 diabetes in patients as young as eight years old. By postponing the requirement for insulin injections, the therapy represents a significant shift in pediatric care. Furthermore, the agency recommended Mavacamten for obstructive hypertrophic cardiomyopathy, citing an improved safety profile over existing therapies, and authorized Resmetirom as one of the first approved treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that previously lacked targeted interventions.

The briefing also addressed the intense public interest in GLP-1 receptor agonists, such as Semaglutide. While the agency is currently assessing oral formulations and generic versions to increase access, it issued a firm Health, not Hype warning against the misuse of these treatments as lifestyle shortcuts. To combat misinformation and promote responsible use, the EMA launched a collaborative campaign with digital content creators, signaling a modernization of its public health communication strategy.

Breakthroughs in Gene Therapy and Orphan Diseases

Innovation in 2025 extended into highly specialized fields, including the approval of Beremagene geperpavec, a disease-modifying gene therapy administered as a topical gel for an ultra-rare blistering skin condition. Another landmark was the approval of Afamitresgene autoleucel for the treatment of inherited immune deficiency linked to Wiskott-Aldrich syndrome. The agency highlighted that this particular development was led by a non-profit foundation, benefiting from an EMA pilot program designed to provide enhanced support to academic and non-commercial developers.

In oncology, the recommendation of Odadextran for non-muscular invasive bladder cancer addressed a high-risk patient population in a disease that affects approximately 200,000 Europeans each year. Additionally, the agency moved to expand treatment options for chronic lung diseases, approving Brensocatib as one of the first approved medicines for non-cystic fibrosis bronchiectasis, a condition affecting up to 3 million people in the EU.

Global Collaboration and the 2026 Innovation Pipeline

Looking toward the upcoming year, the EMA anticipates a sustained momentum in drug development. For the first half of 2026, the agency has received letters of intent for 84 marketing authorization applications, including 58 featuring new active substances and 28 targeting orphan conditions. Oncology and immunomodulating agents are expected to comprise nearly 50% of these submissions, followed by treatments for the musculoskeletal and metabolic systems.

The briefing also touched upon the deepening relationship between the EMA and the U.S. FDA, specifically regarding the ethical and technical integration of artificial intelligence (AI). Following the joint publication of ten guiding principles for AI use in drug development, the agency emphasized that the goal is not for AI to replace human regulators, but to streamline routine tasks, summarize vast documentation, and enhance the review of complex applications.

Modernizing the Regulatory Framework

The EMA is preparing for a once-in-a-generation transformation as the European Union finalizes new pharmaceutical legislation. This legislative overhaul, coupled with the Biotech Act and the Critical Medicines Act, is intended to make the European regulatory system more competitive, particularly in terms of the attractiveness of clinical trials and accelerated approval timelines.

Agency leadership expressed a commitment to refining internal processes during the transition period, aiming to reduce the administrative burden on developers while maintaining high scientific standards. The EMA also recently published a reflection paper on a tailored clinical approach for biosimilars, a move aligned with global regulators like the FDA and Health Canada, which could potentially reduce the volume of clinical data required for approval by leveraging advanced molecular characterization.

Future Outlook

The 2025 review paints a picture of a regulatory body in transition—embracing digital tools and new communication channels while managing a record-setting volume of innovative therapies. As the agency moves into 2026, it remains focused on fostering an ecosystem where regulation and innovation work in tandem to address the continent’s most pressing health challenges, from rare genetic disorders to the widespread impact of cardiovascular disease.